A new clinical trial suggests that a combination of the drug vorinostat and immunotherapy can coax HIV-infected cells out of latency and attack them. The findings highlight how close -- yet still far ...
Hosted on MSN
Purecycle highlights operational and commercial progress with 33 active trials in Q1 2025
CEO Dustin Olson announced that the first quarter marked the company's initial revenue generation. He emphasized operational improvements at the Ironton facility, which achieved 90% onstream time in ...
Context Therapeutics Inc. announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76, a bispecific antibody targeting CLDN6 in advanced cancers, at the 2025 ...
In the second quarter, the firm began dosing patients in three signal-seeking clinical trials to evaluate BNT327, its VEGF x PD-L1 bispecific, in combination with antibody-drug conjugates as ...
All right, seems like everybody has managed to make their way. So I just wanted to say good morning, and thank you for joining Cynata Therapeutics Investor Webinar for the September 2025 quarter.
Hosted on MSN
Patient-centric trials: progress but gaps remain
Patient-centricity has become a buzzword in recent years, with companies touting more inclusive trial designs and bringing patients and advocates into early planning stages. On Clinical Trials Day ...
A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us. Credit...Ricardo Tomás Supported by By Nina Agrawal Nina Agrawal is a health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback